FDA clears study of Neuralstem spinal cord therapy
Adult stem cell developer Neuralstem Inc. said Monday the Food and Drug Administration approved the company's plan for a small, early-stage study of its treatment for spinal cord injury.
The company plans to enroll up to eight patients with a type of spinal cord injury that causes complete paralysis.
All patients in the study will receive six injections of stem cells, followed by physical therapy and drugs to prevent the body from rejecting the stem cells.
Neuralstem is studying several therapeutic uses of adult stem cells. The company completed phase I testing of a treatment for Lou Gehrig's disease in August.
Shares of Neuralstem Inc. rose 5 cents, or 4 percent, to close at $1.29.